Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors

M Lidar, E Giat, D Garelick, Y Horowitz, H Amital… - Autoimmunity …, 2018 - Elsevier
Background The use of immune checkpoint inhibitors (ICI) has grown incessantly since they
were first approved in 2014. These monoclonal antibodies inhibit T cell activation, yielding a …
被引用次数：160 相关文章

[引用][C] Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors

M Lidar, E Giat, D Garelick, Y Horowitz, H Amital… - Autoimmunity …, 2018 - cir.nii.ac.jp
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors

M Lidar, E Giat, D Garelick, Y Horowitz… - Autoimmunity …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The use of immune checkpoint inhibitors (ICI) has grown incessantly since they
were first approved in 2014. These monoclonal antibodies inhibit T cell activation, yielding a …

Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

M Lidar, E Giat, D Garelick, Y Horowitz… - Autoimmunity …, 2018 - europepmc.org
Background The use of immune checkpoint inhibitors (ICI) has grown incessantly since they
were first approved in 2014. These monoclonal antibodies inhibit T cell activation, yielding a …